Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.59 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.59 |
| ▸ | PI4KA | P42356 | 2/20 | 0.59 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.59 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.59 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.59 |
| ▸ | DPP4 | P27487 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.59 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.59 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.59 |
| ▸ | GAPDH | P04406 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | STAT6 | P42226 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lodenosine SCHEMBL3482 | 1.00 | EGFR (0.61) | EGFRERBB2ADORA3ADORA2BADORA2A | |
| Lodenosine SCHEMBL16670086 | 1.00 | EGFR (0.61) | EGFRERBB2ADORA3ADORA2BADORA2A | |
| Lodenosine SCHEMBL29663669 | 1.00 | EGFR (0.61) | EGFRERBB2ADORA3ADORA2BADORA2A | |
| Lodenosine SCHEMBL29831913 | 1.00 | EGFR (0.61) | EGFRERBB2ADORA3ADORA2BADORA2A | |
| Lodenosine SCHEMBL8451244 | 1.00 | EGFR (0.61) | EGFRERBB2ADORA3ADORA2BADORA2A | |
| Lodenosine SCHEMBL3483 | 1.00 | EGFR (0.61) | EGFRERBB2ADORA3ADORA2BADORA2A | |
| Lodenosine SCHEMBL29421139 | 1.00 | EGFR (0.61) | EGFRERBB2ADORA3ADORA2BADORA2A | |
| Lodenosine SCHEMBL29329162 | 1.00 | EGFR (0.61) | EGFRERBB2ADORA3ADORA2BADORA2A | |
| Lodenosine SCHEMBL30998176 | 1.00 | EGFR (0.61) | EGFRERBB2ADORA3ADORA2BADORA2A | |
| Lodenosine SCHEMBL22869478 | 1.00 | EGFR (0.61) | EGFRERBB2ADORA3ADORA2BADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3068 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| US-20260021101-A1 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING OR REVERSING AGE-ASSOCIATED INFLAMMATION AND DISORDERS | BROWN UNIVERSITY (US) | 2026-01-22 | — | — | US | claimed |
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| CN-120145057-A | Soft contrast learning fault diagnosis method based on large language model question-answer dialogue | 武汉理工大学 | 2025-06-13 | — | — | CN | claimed |
| CN-119740406-A | Typhoon vortex initialization method and typhoon vortex initialization system | 南京信息工程大学 | 2025-04-01 | — | — | CN | claimed |
| US-12220464-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-02-11 | — | — | US | claimed |
| WO-1999064048-A9 | INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ADVANCED MEDICINE INC (US) | 2000-07-20 | — | — | WO | claimed |
| EP-1003541-A1 | INHIBITORS OF HIV REVERSE TRANSCRIPTASE | Advanced Medicine, Inc. (US) | 2000-05-31 | — | — | EP | claimed |
| WO-1999064048-A1 | INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| US-5565437-A | 2',3'-dideoxy-2'-fluoro-purine nucleosides and methods for using same | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-10-15 | — | — | US | claimed |
| US-5495010-A | Acid stable purine dideoxynucleosides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-02-27 | — | — | US | claimed |
| EP-0287313-B1 | Acid stable dideoxynucleosides active against the cytopathic effects of human immunodeficiency virus | US COMMERCE (US) | 1995-01-04 | — | — | EP | claimed |
| EP-0464137-A4 | INHIBITION OF HIV USING SYNERGISTIC COMBINATIONS OF NUCLEOSIDE DERIVATIVES | — | 1992-01-15 | — | — | EP | claimed |
| EP-0464137-A1 | INHIBITION OF HIV USING SYNERGISTIC COMBINATIONS OF NUCLEOSIDE DERIVATIVES | ONCOGEN LIMITED PARTNERSHIP (US) | 1992-01-08 | — | — | EP | claimed |
| EP-0428109-A2 | Deoxyfluoronucleoside process | Bristol-Myers Squibb Company (US) | 1991-05-22 | — | — | EP | claimed |
| WO-1990011081-A1 | INHIBITION OF HIV USING SYNERGISTIC COMBINATIONS OF NUCLEOSIDE DERIVATIVES | ONCOGEN LIMITED PARTNERSHIP (US) | 1990-10-04 | — | — | WO | claimed |